We believe this site might serve you best:

United States

United States

Language: English

Promega's Cookie Policy

Our website uses functional cookies that do not collect any personal information or track your browsing activity. When you select your country, you agree that we can place these functional cookies on your device.

Our website does not fully support your browser.

We've detected that you are using an older version of Internet Explorer. Your commerce experience may be limited. Please update your browser to Internet Explorer 11 or above.

Limited Functionality Warning

We are currently updating our network. During this time, certain functionality may be unavailable, including online orders. We apologize for any inconvenience this may cause you.

Please contact Customer Service with any questions or comments.
Phone: (608) 274-4330
Toll-Free Phone: (800) 356-9526
Email: custserv@promega.com
Hours: 7am – 6pm, CST, Monday-Friday

HaloTag™ Interchangeable Labeling Technology for Cell Imaging Protein Capture and Immobilization

  • Print
  • Email

Abstract

The HaloTag™ Interchangeable Labeling Technology is designed to provide new options for rapid, site-specific labeling of proteins in living cells and in vitro. The technology is based on the efficient formation of a covalent bond between the HaloTag™ Protein and synthetic ligands. The covalent bond forms rapidly under physiological conditions, is highly specific and essentially irreversible, yielding a stable complex even under denaturing conditions. The HaloTag™ Ligand can carry a variety of functionalities, including fluorescent labels, affinity handles and attachments to a solid phase. The flexibility to create labeled HaloTag™ fusion proteins with a wide range of optical properties and functions will allow researchers to image and localize labeled HaloTag™ Protein fusions in live- or fixed-cell populations as well as isolate and analyze HaloTag™ Protein fusions and protein complexes.

Promega Notes 89, 2–6.

Georgyi V. Los1, Al Darzins1, Chad Zimprich1, Natasha Karassina1, Randall Learish1, Mark G. McDougall2, Lance P. Encell1, Rachel Friedman-Ohana1, Monika Wood1, Gediminas Vidugiris1, Kris Zimmerman1, Paul Otto1, Dieter H. Klaubert2 and Keith Wood1

1Promega Corporation, 2Promega Biosciences, Incorporated
Publication Date: 2005

Download Article (343 KB)